GRI Bio, Inc.

GRI Bio, Inc. (VLON) priced its initial public offering on Feb 11, 2021 at $8.00 per share, within its $8.00–$10.00 range, raising $18M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $54M. ThinkEquity was lead-left underwriter. Thompson Hine advised the company and Ellenoff Grossman & Schole advised the underwriters.

GRI Bio, Inc. is a biopharmaceutical company developing prescription drugs for central nervous system disorders, with a focus on drugs with lower abuse potential. Its clinical-stage product, ADAIR, is an abuse-deterrent immediate-release dextroamphetamine formulation for ADHD and narcolepsy.

Status

IPO

Ticker

VLON

Exchange

Nasdaq Capital Market

Priced

Feb 11, 2021

IPO price

$8.00

Price range

$8.00–$10.00

Raised

$18M

Market cap at IPO price

$54M

First filed

Oct 23, 2020

Underwriters

ThinkEquity

Company counsel

Thompson Hine

Underwriters' counsel

Ellenoff Grossman & Schole

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.